Trial · NCT07883564
Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients
NCT07883564, Not yet recruiting, Cardiology Consultants of Philadelphia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients. Trials, record NCT07883564. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883564
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients
- NCT number
- NCT07883564
- Status
- Not yet recruiting
- Enrollment
- 2,500 participants, estimated
- Lead sponsor
- Cardiology Consultants of Philadelphia
- Conditions
- ASCVD
- First posted
- 2026-10-20
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binary indicator of LDL-C <55 mg/dL for patients with a recent MI or coronary stent and <70 mg/dL for patients undergoing PCI with no MI and/or ischemic heart disease or with a CAC score of at least 300 at 6-month post visit, with time to event. | Within 6-months post qualifying event. | LDL-C level/goal attainment per guidelines. LDL-C laboratory testing. |
| Primary | Binary indicator of patients who received LDL-C testing, with time to event. | Up to 365 days following qualifying event. | LDL-C laboratory testing. |
| Primary | Binary indicator of patients in whom lipid lowering therapy was initiated/intensified within the first six months after index event. | Within 6-months post qualifying event. | Any change in prescriptions/dosages of lipid lowering medications (statins, ezetimibe, BAS, PCSK9 inhibitors, bempedoic acid +/- ezetimibe, fibrates, prescription OM3FA). |
| Secondary | Persistence of cardiovascular risk goals after being discharged from the APP pathway strategy: Prescription of GLP1/SGLT2 inhibitors | Up to 365 days following qualifying event. | Prescription or removal of GLP1/SGLT2 inhibitor medications. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Cardiac Rehab | Up to 365 days following qualifying event. | Binary indication of whether cardiac rehab was ordered and initiated. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Blood Pressure | Up to 365 days following qualifying event. | Self-reported home measurement or in-office measurement of blood pressure. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: BMI | Up to 365 days following qualifying event. | Height in inches and weight in pounds as measured during office visit will be combined to report BMI in lbs/in\^2. |
| Secondary | Persistence of cardiovascular risk after discharge from the APP pathway strategy: Smoking Status | Up to 365 days following qualifying event. | Binary indicator of smoking status. |
| Secondary | Binary indicator of LDL-C <55 mg/dL for patients with a recent MI or coronary stent and <70 mg/dL patients undergoing PCI with no MI and/or ischemic heart disease and for those with a CAC score > 300 at 3- and 12-month post visit, with time to event. | Up to 365 days following qualifying event. | LDL-C laboratory testing, LDL-C level/goal attainment per guidelines. |
| Secondary | Binary indicator of patients in whom LLT was initiated/intensified at the 3- and 12-month visits post-index. | Up to 365 days following qualifying event. | Any change in prescriptions/dosages of lipid lowering medications (statins, ezetimibe, BAS, PCSK9 inhibitors, bempedoic acid +/- ezetimibe, fibrates, prescription OM3FA). |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883564
GET https://conductscience.org/api/trials/v1/NCT07883564/registered?page=2